Kestra Investment Management LLC Makes New $437,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kestra Investment Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, Holdings Channel reports. The fund purchased 416 shares of the biopharmaceutical company’s stock, valued at approximately $437,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. West Paces Advisors Inc. raised its holdings in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares in the last quarter. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $26,000. Sachetta LLC grew its stake in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares during the last quarter. Crewe Advisors LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth $28,000. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $33,000. Institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Joseph J. Larosa sold 1,866 shares of the business’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the completion of the transaction, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at $41,311,496.15. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Joseph J. Larosa sold 1,866 shares of the business’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $1,088.95, for a total value of $2,031,980.70. Following the sale, the executive vice president now directly owns 37,937 shares of the company’s stock, valued at $41,311,496.15. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,033 shares of company stock worth $9,399,345. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $1,051.24 on Tuesday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The business’s fifty day moving average price is $1,128.54 and its two-hundred day moving average price is $1,036.16. The stock has a market capitalization of $115.83 billion, a price-to-earnings ratio of 31.06, a price-to-earnings-growth ratio of 3.57 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the previous year, the business earned $8.79 EPS. Regeneron Pharmaceuticals’s revenue was up 12.3% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Leerink Partners reissued a “market perform” rating and set a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, September 16th. JPMorgan Chase & Co. boosted their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Argus increased their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,118.62.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.